Adant Dispo should be administered with care in the following patients:
Patients with a history of hypersensitivity to other drugs.
Patients with hepatic disorder or with a history thereof. [Abnormal values of AST (GOT), ALT (GPT) were seen in a patient with a history of hepatic disorder.]
Patients with dermatosis or infection in the joint (since Adant Dispo is injected into the joint).
Important Precautions: Adant Dispo may worsen local inflammation in patients with osteoarthritis of the knee who present with marked inflammation of the joint. Therefore, it is advisable to administer this product after the local symptom has alleviated.
Local pain may infrequently occur due to the administration of Adant Dispo. To avoid pain after the injection, the patient should be instructed to stay still for a while.
Adant Dispo must be injected exactly into the intra-articular space. Otherwise, it may cause pain.
Use in pregnancy & lactation: Adant Dispo should be used in pregnant women or women who may possibly become pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment. (No teratogenicity was detected in rabbits, but its safety in pregnant women has not been established.)
Breastfeeding must be discontinued during the administration of Adant Dispo. (Transfer of the product in milk has been confirmed in rats.)
Use in children: The safety of Adant Dispo in low birth weight infants, newborns, suckling infants, infants and children has not been established.
Use in the elderly: Since elderly patients often have reduced physiological functions, Adant Dispo should be administered with care.